Baylor Genetics

Executive Summary

Baylor Genetics is a Houston-based private diagnostics company founded in 2011 that specializes in clinically relevant genetic testing and precision medicine. The company offers a wide range of tests to determine an individual's risk of developing or passing on genetic disorders, leveraging deep expertise in genetics to provide actionable insights for patients and healthcare providers. With a focus on high-quality, clinically validated assays, Baylor Genetics serves as a key partner in the growing field of genomic medicine, addressing unmet needs in rare disease diagnosis, cancer predisposition, and pharmacogenomics. The company's strong academic affiliations and reputation for accuracy position it as a leader in the genetic testing space. As the demand for precision medicine accelerates, Baylor Genetics is poised to expand its test menu and market reach. The company's growth is driven by increasing awareness of genetic testing, technological advancements, and broader insurance coverage. While private, Baylor Genetics may pursue strategic partnerships or new product launches to capture market share. The following catalysts highlight potential near-term events that could drive value, though the company's private nature limits visibility into specific timelines. Overall, Baylor Genetics occupies a strong niche in a high-growth industry, with opportunities to scale through innovation and collaboration.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for New Liquid Biopsy Test60% success
• Q4 2026Expansion into New Geographic Markets (e.g., Asia-Pacific)50% success
• Q2 2026Strategic Partnership with Major Health System or Pharma70% success